Literature DB >> 29093991

Fibroblast Growth Factor 19 Activates the Unfolded Protein Response and Mitogen-Activated Protein Kinase Phosphorylation in H-69 Cholangiocyte Cells.

Hannan A Qureshi1, Jeffrey A Pearl1, Kristy A Anderson1, Richard M Green1.   

Abstract

BACKGROUND: Cholangiocytes are injured in many biliary tract diseases that result in cirrhosis, cholangiocarcinoma and need for liver transplantation. Recent studies demonstrate that the hormone Fibroblast Growth Factor 19 (FGF19) is produced in the ileum and regulates hepatic gene expression via the enterohepatic circulation. However, the role of FGF19 on cholangiocytes remains largely unknown. The purpose of this study was to elucidate the effect of FGF19 on cholangiocyte gene and protein expression.
METHODS: Cultured human cholangiocyte-derived H69 cells were treated with FGF19 (0-50ng/ml) and expression of genes and proteins involved in the Unfolded Protein Response (UPR) and mitogen-activated protein kinase (MAPK) pathways were studied using RT-PCR and Western blot analysis.
RESULTS: FGF19-induced gene and protein expression of the UPR genes BiP and CHOP increased in a dose-responsive pattern. The UPR protein P-eIF2a displayed a bimodal pattern of protein expression, with 10ng/ml of FGF19 maximally reducing and 50ng/ml maximally increasing expression. MAPK pathway protein expression (P-JNK, P-ERK, P-38) displayed a similar bimodal pattern of expression with 2.5ng/ml of FGF19 decreasing expression and 25ng/ml of FGF19 increasing expression.
CONCLUSIONS: FGF19 treatment of H69 cells selectively activates BiP and CHOP in a dose-dependent manner. FGF19 also regulates P-eIF2a and MAPK protein expression with a bimodal response. We speculate that FGF19 has an important role in the pathogenesis of many human cholangiopathies and cholestatic liver disorders.

Entities:  

Keywords:  Fibroblast Growth Factor 19; Mitogen-Activated Protein Kinases; Unfolded Protein Response

Year:  2014        PMID: 29093991      PMCID: PMC5662007          DOI: 10.4172/2167-0889.1000158

Source DB:  PubMed          Journal:  J Liver        ISSN: 2167-0889


  31 in total

1.  Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.

Authors:  Hiroshi Kurosu; Mihwa Choi; Yasushi Ogawa; Addie S Dickson; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Kevin P Rosenblatt; Steven A Kliewer; Makoto Kuro-o
Journal:  J Biol Chem       Date:  2007-07-10       Impact factor: 5.157

Review 2.  The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.

Authors:  Antonella De Luca; Monica R Maiello; Amelia D'Alessio; Maria Pergameno; Nicola Normanno
Journal:  Expert Opin Ther Targets       Date:  2012-03-23       Impact factor: 6.902

Review 3.  Primary sclerosing cholangitis.

Authors:  Y M Lee; M M Kaplan
Journal:  N Engl J Med       Date:  1995-04-06       Impact factor: 91.245

4.  FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4.

Authors:  M H Xie; I Holcomb; B Deuel; P Dowd; A Huang; A Vagts; J Foster; J Liang; J Brush; Q Gu; K Hillan; A Goddard; A L Gurney
Journal:  Cytokine       Date:  1999-10       Impact factor: 3.861

5.  Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis.

Authors:  Sushant Bhatnagar; Holly A Damron; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2009-02-20       Impact factor: 5.157

6.  A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.

Authors:  Katrina Nicholes; Susan Guillet; Elizabeth Tomlinson; Kenneth Hillan; Barbara Wright; Gretchen D Frantz; Thinh A Pham; Lisa Dillard-Telm; Siao Ping Tsai; Jean-Philippe Stephan; Jeremy Stinson; Timothy Stewart; Dorothy M French
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

7.  Mortality attributable to cholestatic liver disease in the United States.

Authors:  Flavia D Mendes; W Ray Kim; Rachel Pedersen; Terry Therneau; Keith D Lindor
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425

8.  Liver-specific activities of FGF19 require Klotho beta.

Authors:  Benjamin C Lin; Manping Wang; Craig Blackmore; Luc R Desnoyers
Journal:  J Biol Chem       Date:  2007-07-11       Impact factor: 5.157

9.  FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.

Authors:  Serkan Kir; Sara A Beddow; Varman T Samuel; Paul Miller; Stephen F Previs; Kelly Suino-Powell; H Eric Xu; Gerald I Shulman; Steven A Kliewer; David J Mangelsdorf
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.

Authors:  Ai-Luen Wu; Sally Coulter; Christopher Liddle; Anne Wong; Jeffrey Eastham-Anderson; Dorothy M French; Andrew S Peterson; Junichiro Sonoda
Journal:  PLoS One       Date:  2011-03-18       Impact factor: 3.240

View more
  3 in total

Review 1.  Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis.

Authors:  Takeshi Katafuchi; Makoto Makishima
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

2.  Fibroblast Growth Factor 19 Induced Changes in Non-malignant Cholangiocytes.

Authors:  Jiaqi Yang; David Sontag; Sam Kung; Gerald Y Minuk
Journal:  J Clin Transl Hepatol       Date:  2021-06-04

3.  MicroRNA-455-5p Contributes to Cholangiocarcinoma Growth and Mediates Galangin's Anti-Tumor Effects.

Authors:  Xu Deng; Meiling Zuo; Zhifang Pei; Yuanlin Xie; Zhongbao Yang; Zhihui Zhang; Minna Jiang; Dabin Kuang
Journal:  J Cancer       Date:  2021-06-04       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.